Search

Your search keyword '"Schnabel, Marco J."' showing total 25 results
Start Over Author "Schnabel, Marco J."
25 results on '"Schnabel, Marco J."'

1. Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre

Author

Scheiter, Alexander, Hierl, Frederik, Lüke, Florian, Keil, Felix, Heudobler, Daniel, Einhell, Sabine, Klier-Richter, Margit, Konstandin, Nikola P., Weber, Florian, Scheiter, Andrea, Kandulski, Arne, Schlosser, Sophie, Cosma, Lidia-Sabina, Tews, Hauke, Weiss, Andreas R. R., Grube, Matthias, Bumes, Elisabeth, Hau, Peter, Proescholdt, Martin, Steger, Felix, Troeger, Anja, Haferkamp, Sebastian, Reibenspies, Lucas E., Schnabel, Marco J., Schulz, Christian, Drexler, Konstantin, Hatzipanagiotou, Maria E., Seitz, Stephan, Klinkhammer-Schalke, Monika, Unberath, Philipp, Calvisi, Diego F., Pukrop, Tobias, Dietmaier, Wolfgang, Evert, Matthias, and Utpatel, Kirsten

Published
2023
Full Text
View/download PDF

2. Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitals

Author

Struck, Julian P., Schnoor, Maike, Schulze, Andrea, Hupe, Marie C., Ozimek, Tomasz, Oppolzer, Immanuel A., Schnabel, Marco J., Burger, Maximilian, Darr, Christopher, Gruenwald, Viktor, Hadaschik, Boris, Weinke, Maximilian, Kuebler, Hubert, Klockenbusch, Jonas C., Grabbert, Markus T., Gratzke, Christian, Kramer, Mario W., Katalinic, Alexander, and Merseburger, Axel S.

Published
2022
Full Text
View/download PDF

7. Patient’s Desire and Real Availability Concerning Supportive Measures Accompanying Radical Prostatectomy: Differences between Certified Prostate Cancer Centers and Non-Certified Centers Based on Patient-Reported Outcomes within the Cross-Sectional Study Improve

Author

Wolff, Ingmar, primary, Burchardt, Martin, additional, Peter, Julia, additional, Thomas, Christian, additional, Sikic, Danijel, additional, Fiebig, Christian, additional, Promnitz, Sören, additional, Hoschke, Bernd, additional, Burger, Maximilian, additional, Schnabel, Marco J., additional, Gilfrich, Christian, additional, Löbig, Niklas, additional, Harke, Nina N., additional, Distler, Florian A., additional, and May, Matthias, additional

Published
2023
Full Text
View/download PDF

9. Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre

Author

Scheiter, Alexander, primary, Hierl, Frederik, additional, Lüke, Florian, additional, Keil, Felix, additional, Heudobler, Daniel, additional, Einhell, Sabine, additional, Klier-Richter, Margit, additional, Konstandin, Nikola P., additional, Weber, Florian, additional, Scheiter, Andrea, additional, Kandulski, Arne, additional, Schlosser, Sophie, additional, Cosma, Lidia-Sabina, additional, Tews, Hauke, additional, Weiss, Andreas R. R., additional, Grube, Matthias, additional, Bumes, Elisabeth, additional, Hau, Peter, additional, Proescholdt, Martin, additional, Steger, Felix, additional, Troeger, Anja, additional, Haferkamp, Sebastian, additional, Reibenspies, Lucas E., additional, Schnabel, Marco J., additional, Schulz, Christian, additional, Drexler, Konstantin, additional, Hatzipanagiotou, Maria E., additional, Seitz, Stephan, additional, Klinkhammer-Schalke, Monika, additional, Unberath, Philipp, additional, Calvisi, Diego F., additional, Pukrop, Tobias, additional, Dietmaier, Wolfgang, additional, Evert, Matthias, additional, and Utpatel, Kirsten, additional

Published
2022
Full Text
View/download PDF

10. Patients Regret Their Choice of Therapy Significantly Less Frequently after Robot-Assisted Radical Prostatectomy as Opposed to Open Radical Prostatectomy: Patient-Reported Results of the Multicenter Cross-Sectional IMPROVE Study

Author

Wolff, Ingmar, primary, Burchardt, Martin, additional, Gilfrich, Christian, additional, Peter, Julia, additional, Baunacke, Martin, additional, Thomas, Christian, additional, Huber, Johannes, additional, Gillitzer, Rolf, additional, Sikic, Danijel, additional, Fiebig, Christian, additional, Steinestel, Julie, additional, Schifano, Paola, additional, Löbig, Niklas, additional, Bolenz, Christian, additional, Distler, Florian A., additional, Huettenbrink, Clemens, additional, Janssen, Maximilian, additional, Schilling, David, additional, Barakat, Bara, additional, Harke, Nina N., additional, Fuhrmann, Christian, additional, Manseck, Andreas, additional, Wagenhoffer, Robert, additional, Geist, Ekkehard, additional, Blair, Lisa, additional, Pfitzenmaier, Jesco, additional, Reinhardt, Bettina, additional, Hoschke, Bernd, additional, Burger, Maximilian, additional, Bründl, Johannes, additional, Schnabel, Marco J., additional, and May, Matthias, additional

Published
2022
Full Text
View/download PDF

12. Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial

Author

Pal, Sumanta K, primary, Somford, Diederik M, additional, Grivas, Petros, additional, Sridhar, Srikala S, additional, Gupta, Shilpa, additional, Bellmunt, Joaquim, additional, Sonpavde, Guru, additional, Fleming, Mark T, additional, Lerner, Seth P, additional, Loriot, Yohann, additional, Hoffman-Censits, Jean, additional, Valderrama, Begoña P, additional, Andresen, Corina, additional, Schnabel, Marco J, additional, Cole, Suzanne, additional, and Daneshmand, Siamak, additional

Published
2022
Full Text
View/download PDF

13. Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment—A Retrospective Multicenter Analysis

Author

Riedel, Felix, primary, Münker, Mara, additional, Roghmann, Florian, additional, Breyer, Johannes, additional, Schnabel, Marco J., additional, Burger, Maximilian, additional, Sikic, Danijel, additional, Büttner, Thomas, additional, Ritter, Manuel, additional, Hiller, Kiriaki, additional, Wezel, Felix, additional, Bolenz, Christian, additional, and Zengerling, Friedemann, additional

Published
2022
Full Text
View/download PDF

14. Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitals

Author

Struck, Julian P., primary, Schnoor, Maike, additional, Schulze, Andrea, additional, Hupe, Marie C., additional, Ozimek, Tomasz, additional, Oppolzer, Immanuel A., additional, Schnabel, Marco J., additional, Burger, Maximilian, additional, Darr, Christopher, additional, Gruenwald, Viktor, additional, Hadaschik, Boris, additional, Weinke, Maximilian, additional, Kuebler, Hubert, additional, Klockenbusch, Jonas C., additional, Grabbert, Markus T., additional, Gratzke, Christian, additional, Kramer, Mario W., additional, Katalinic, Alexander, additional, and Merseburger, Axel S., additional

Published
2021
Full Text
View/download PDF

15. Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making

Author

Aziz, Atiqullah, Shariat, Shahrokh F., Roghmann, Florian, Brookman-May, Sabine, Stief, Christian G., Rink, Michael, Chun, Felix K., Fisch, Margit, Novotny, Vladimir, Froehner, Michael, Wirth, Manfred P., Schnabel, Marco J., Fritsche, Hans-Martin, Burger, Maximilian, Pycha, Armin, Brisuda, Antonin, Babjuk, Marko, Vallo, Stefan, Haferkamp, Axel, Roigas, Jan, Noldus, Joachim, Stredele, Regina, Volkmer, Björn, Bastian, Patrick J., Xylinas, Evanguelos, and May, Matthias

Published
2016
Full Text
View/download PDF

17. Targeting alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.

Author

Pal, Sumanta K, Somford, Diederik M, Grivas, Petros, Sridhar, Srikala S, Gupta, Shilpa, Bellmunt, Joaquim, Sonpavde, Guru, Fleming, Mark T, Lerner, Seth P, Loriot, Yohann, Hoffman-Censits, Jean, Valderrama, Begoña P, Andresen, Corina, Schnabel, Marco J, Cole, Suzanne, and Daneshmand, Siamak

Subjects
BLADDER tumors, ADJUVANT chemotherapy, CLINICAL trials, UREA, HETEROCYCLIC compounds, CELL receptors, ANTINEOPLASTIC agents, TRANSITIONAL cell carcinoma, RESEARCH funding
Abstract

PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk muscle-invasive upper tract urothelial cancer (85% of patients) or urothelial bladder cancer (15%), susceptible FGFR3 alterations (activating mutations, gene fusions or rearrangements), ≤120 days following radical surgery and ineligible for/or refusing cisplatin-based (neo)adjuvant chemotherapy. Patients receive either oral infigratinib 125 mg or placebo daily on days 1-21 of a 28-day cycle for up to 52 weeks or until recurrence, unacceptable toxicity or death. Primary end point: centrally determined disease-free survival (DFS); secondary end points: investigator-assessed DFS, metastasis-free survival, overall survival and safety/tolerability; exploratory end points: correlative biomarker analysis, quality-of-life and infigratinib pharmacokinetics. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

19. Impact of Male Patient Information on Quality of Urine Examination (PIQUE Study).

Author

Spachmann, Philipp J., Rupp, Cathrin, Fritsche, Hans-Martin, Denzinger, Stefan, Burger, Maximilian, Breyer, Johannes, Otto, Wolfgang, and Schnabel, Marco J.

Subjects
URINALYSIS, URINARY tract infections
Abstract

Background: Urine examination has relevance for treatment, and reliability of positive urine culture (UC) is of importance. The technique of urine sampling (US), storage, and transportation is important. The objective of this study was to investigate if detailed patient information for the technique of US and hygiene reduces rates of contaminated UC in screened male patients, as this group was not investigated yet. Methods: All patients independently of complaints were enrolled prospectively and consecutively in an outpatient setting in 2 groups – the first group did not receive detailed information and the second group did. We examined 372 consecutive patients in 2017, 190 not receiving (median age 69 years) and 182 receiving information (median age 70 years), with comparable numbers of patients and age. The result of UC and age was imposed. Results: In all,74.2% of preclarification UC showed a contamination (n = 95) and 75.5% after clarification (n = 83), without significant differences (p = 0.827). This study is limited by the fact that adherence could not be checked. Conclusions: Similar to studies with females, no difference occurred in rates of contaminated UC, so detailed information regarding the US technique does not decrease rates of contaminated UC and vice versa does not increase the quality of midstream-sampled UC in male patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making

Author

Aziz, Atiqullah, primary, Shariat, Shahrokh F., additional, Roghmann, Florian, additional, Brookman-May, Sabine, additional, Stief, Christian G., additional, Rink, Michael, additional, Chun, Felix K., additional, Fisch, Margit, additional, Novotny, Vladimir, additional, Froehner, Michael, additional, Wirth, Manfred P., additional, Schnabel, Marco J., additional, Fritsche, Hans-Martin, additional, Burger, Maximilian, additional, Pycha, Armin, additional, Brisuda, Antonin, additional, Babjuk, Marko, additional, Vallo, Stefan, additional, Haferkamp, Axel, additional, Roigas, Jan, additional, Noldus, Joachim, additional, Stredele, Regina, additional, Volkmer, Björn, additional, Bastian, Patrick J., additional, Xylinas, Evanguelos, additional, and May, Matthias, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results